Eucrates Biomedical Acquisition Corp. (EUCR) Research
Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises. Specifically, it aims to find and acquire a company operating within the life sciences or broader healthcare sectors across North America and Europe. Established in 2020, this entity has its headquarters situated in New York, New York.
Market snapshot
- Symbol
- EUCR
- Price
- $10.04
- Day change
- 0.00%
- Market cap
- $42.2M
- P/E ratio
- 5.40x
- 52-week range
- 9.87-10.25
- Sector
- Financial Services
- Industry
- Shell Companies
Peer companies
- Artemis Strategic Investment Corporation (ARTEU)
- Broad Capital Acquisition Corp. (BRACU)
- BYTE Acquisition Corp. (BYTSW)
- Forum Merger IV Corporation (FMIV)
- Finnovate Acquisition Corp. (FNVT)
- Forbion European Acquisition Corp. (FRBNU)
- The Growth for Good Acquisition Corporation (GFGD)
- Mountain Crest Acquisition Corp. IV (MCAFU)
Recent insider activity
- PAPADOPOULOS STELIOS — J-Other (255094 shares) on 2020-11-24
- PAPADOPOULOS STELIOS — trade (0 shares) on 2020-10-23
- CAMPBELL WILLIAM I — trade (0 shares) on 2020-10-23
Open Eucrates Biomedical Acquisition Corp. (EUCR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.